论文部分内容阅读
Fragment-based drug screening is an emerging technology that involves screening low MW molecules with low binding affinities.As a result, sensitive biophysical screening methods such as X-ray, NMR and SPR are required to detect weak binders.Fragment based drug discovery has been used to generate leads that have been progressed into clinical trials.In this presentation, I will give an overview of the current status of fragrnent-based drug discovery and examples where fragment screening has resulted in novel, efficient templates.